Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (FATE)
NASDAQ:FATE
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 13.63M | $ 63.53M | $ 96.30M | $ 55.85M | $ 31.43M |
| Gross Profit | $ 13.63M | $ -98.16M | $ 82.54M | $ 50.00M | $ -94.19M |
| Operating Income | $ -210.28M | $ -190.51M | $ -308.39M | $ -216.99M | $ -128.09M |
| EBITDA | $ -176.58M | $ -172.23M | $ -294.63M | $ -211.14M | $ -125.00M |
| Net Income | $ -186.26M | $ -160.93M | $ -255.06M | $ -206.30M | $ -170.30M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 279.07M | $ 315.18M | $ 436.23M | $ 615.91M | $ 482.92M |
| Total Assets | $ 440.69M | $ 506.22M | $ 705.56M | $ 921.46M | $ 622.46M |
| Total Debt | $ 85.27M | $ 103.54M | $ 109.34M | $ 114.82M | $ 97.30M |
| Net Debt | $ 49.21M | $ 61.67M | $ 48.01M | $ -18.77M | $ -70.05M |
| Total Liabilities | $ 121.97M | $ 137.80M | $ 221.62M | $ 242.62M | $ 238.01M |
| Stockholders' Equity | $ 318.73M | $ 368.42M | $ 483.94M | $ 678.84M | $ 384.44M |
| Cash Flow | |||||
| Free Cash Flow | $ -123.60M | $ -138.42M | $ -283.77M | $ -213.57M | $ -44.16M |
| Operating Cash Flow | $ -122.87M | $ -132.26M | $ -248.21M | $ -162.87M | $ -39.23M |
| Investing Cash Flow | $ 12.22M | $ 112.67M | $ 166.75M | $ -324.02M | $ -161.08M |
| Financing Cash Flow | $ 99.89M | $ 85.00K | $ 9.21M | $ 453.13M | $ 282.84M |